Pharmaceutical Technology Europe-02-01-2010

Pharmaceutical Technology Europe

Implications and Opportunities of Applying QbD Principles to Analytical Measurements

February 01, 2010

Analytics

22

2

The authors present two concepts to improve robustness and facilitate continuous improvement in analytical methods.

Is change good for you?

February 01, 2010

22

2

With the pharmaceutical industry being in a current state of unrest in light of the recent spate of mergers, acquisitions, job cuts, divestments, patent expiries, and so on, we wanted to know how you felt about all these changes that will have directly or indirectly affected you.

Rise of the robots

February 01, 2010

Interview

22

2

Although once used only for large production processes, robotics are now working their way into every aspect of the pharma manufacturing processes.

Commercialising cellular therapies faster

February 01, 2010

Special Feature

22

2

There is much scientific evidence of the early successes of whole cell therapies as disease cures in chronic conditions and disease-modifiers in acute conditions, but limited cases of successfully transferring these discoveries to commercial products or therapies.

Cushioning pharma's fall from the patent precipice

February 01, 2010

Regulation

22

2

Pharma faces imminent expiries of key patents and increasing competition from generics. To protect what they already have, or what they will invent or acquire, companies must give patent protection the attention it deserves.

Achieving site-specific PEGylation

February 01, 2010

Special Feature

22

2

PEGylation has been around for 30 years and it is surprising that it is still widely used given the significant advances that have been made in biopharmaceutical manufacture since then. So why is this the case?

Boosting efficiency and safety by minimising aggregation

February 01, 2010

Special Feature

22

2

Last year, the UK's National Institute for Health and Clinical Excellence (NICE) decided that a new biopharmaceutical cancer drug costing £3000 per month, which could extend a patient's life by 6 months, was not value for money and would not be prescribed in the UK.

Trends and challenges of biopharma manufacturing

February 01, 2010

Special Feature

22

2

The whole pharma/biopharma industry is under pressure to deliver cost-effective new drugs; however, the number of new drug applications is getting lower as the size of investment is increasing.